Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease
Authors:
- Barbora SvobodovaBSBarbora Svobodova
- Lenka PulkrabkovaLPLenka Pulkrabkova
- Dawid PanekDPDawid Panek
- Anna MisiachnaAMAnna Misiachna
- Marharyta KolchevaMKMarharyta Kolcheva
- Rudolf AndrysRARudolf Andrys
- Jiri HandlJHJiri Handl
- Jan CapekJCJan Capek
- Pavlina NyvltovaPNPavlina Nyvltova
- Tomas RousarTRTomas Rousar
- Lukas PrchalLPLukas Prchal
- Vendula HepnarovaVHVendula Hepnarova
Open Access
- 23 May 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9124
Abstract
Alzheimer’s disease (AD) is a complex disease with an unknown etiology. Available treatments, limited to cholinesterase inhibitors and N-methyl-d-aspartate receptor (NMDAR) antagonists, provide symptomatic relief only. As single-target therapies have not proven effective, rational specific-targeted combination into a single molecule represents a more promising approach for treating AD, and is expected to yield greater benefits in alleviating symptoms and slowing disease progression. In the present study, we designed, synthesized, and biologically evaluated 24 novel N-methylpropargylamino-quinazoline derivatives. Initially, compounds were thoroughly inspected by in silico techniques determining their oral and CNS availabilities. We tested, in vitro, the compounds’ effects on cholinesterases and monoamine oxidase A/B (MAO-A/B), as well as their impacts on NMDAR antagonism, dehydrogenase activity, and glutathione levels. In addition, we inspected selected compounds for their cytotoxicity on undifferentiated and differentiated neuroblastoma SH-SY5Y cells. We collectively highlighted II-6h as the best candidate endowed with a selective MAO-B inhibition profile, NMDAR antagonism, an acceptable cytotoxicity profile, and the potential to permeate through BBB. The structure-guided drug design strategy applied in this study imposed a novel concept for rational drug discovery and enhances our understanding on the development of novel therapeutic agents for treating AD.Keywords
Funding Information
- Grantová Agentura České Republiky (22-24384S, LX22NPO510, DZRO-FVZ22-ZHN II)
- Next Generation EU (22-24384S, LX22NPO510, DZRO-FVZ22-ZHN II)
- Ministry of Defence of the Czech Republic—DRO of the University of Defence, Faculty of Military Health Sciences Hradec Kralove, Czech Republic—Medical issues of WMD II (22-24384S, LX22NPO510, DZRO-FVZ22-ZHN II)
This publication has 65 references indexed in Scilit:
- Oximes: Inhibitors of Human Recombinant Acetylcholinesterase. A Structure-Activity Relationship (SAR) StudyInternational Journal of Molecular Sciences, 2013
- NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic lossCell Death & Disease, 2013
- Design, Synthesis, and Structure–Activity Relationships of Highly Potent 5-HT3Receptor LigandsJournal of Medicinal Chemistry, 2012
- Synaptic plasticity of NMDA receptors: mechanisms and functional implicationsCurrent Opinion in Neurobiology, 2012
- Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's diseaseBMC Neurology, 2011
- Characteristics of known drug space. Natural products, their derivatives and synthetic drugsEuropean Journal of Medicinal Chemistry, 2010
- Glutamate Receptor Ion Channels: Structure, Regulation, and FunctionPharmacological Reviews, 2010
- Alzheimer's DiseaseNew England Journal of Medicine, 2010
- Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtinNature Medicine, 2009
- Clinical Pharmacokinetics of TacrineClinical Pharmacokinetics, 1995